HYDERABAD: Hyderabad-based Zenara Pharma, a fully-owned subsidiary of Biophore India Pharmaceuticals, on Thursday said it has received emergency use authorisation (EUA) from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market in India a generic version of Pfizer’s Covid-19 pill Paxlovid for the treatment of patients with mild to moderate Covid-19 symptoms.
The approval is for Nirmatrelvir and Ritonavir tablets in a combipack and will be sold under the Paxzen brand in India. The drug is being manufactured at Zenara’s USFDA approved facility in Hyderabad.
